BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameBCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital)
Drug Alias NameBCMA-CD19 CAR-T Therapy(Peking University People's Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-GPRC5DAnti-BCMAT lymphocyte replacements
TargetsG-protein coupled receptor family C group 5member DB-cell maturation protein
Therapy Area/IndicationsAcquired thrombotic thrombocytopenic purpuraImmunoglobulin G4-Related DiseaseAntiphospholipid Syndrome +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPeking University People'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPeking University People'S Hospital
Inactive CompaniesN/A
Active IndicationsAcquired thrombotic thrombocytopenic purpuraImmunoglobulin G4-Related DiseaseAntiphospholipid Syndrome +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A